The author of today’s article notes that, while the “upside in biotech sector has been led by positive developments at small companies, primarily the ones developing a vaccine or treatment for coronavirus,” there are also biotechs not focused on the fight against COVID-19 that hold potential. They proceed to recommend four ‘Strong Buy’ or ‘Buy’ biotech stocks that “have witnessed share price appreciation and positive estimate revisions in the past 60 days.” For more, CLICK HERE.